Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial

NCT02533232 is registered in ClinicalTrials.gov with Pakistan Institute of Living and Learning as lead sponsor.

NCT NCT02533232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02533232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial
Lead sponsor
Pakistan Institute of Living and Learning
Phase
Phase 1
Overall status
Unknown status
Start date
August 30, 2022
Completion date
December 30, 2022
Enrollment
60 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia, schizophreniform disorder